Recycling tenofovir in second-line antiretroviral treatment with dolutegravir: outcomes and viral load trajectories to 72 weeks

BACKGROUND: Recycling tenofovir and lamivudine/emtricitabine with dolutegravir (TLD) after failure of non-nucleoside transcriptase inhibitor (NNRTI) first-line antiretroviral therapy (ART) is more tolerable and scalable than dolutegravir plus optimized nucleoside reverse transcriptase inhibitors. St...

Descripción completa

Detalles Bibliográficos
Autores principales: Keene, Claire M, Cassidy, Tali, Zhao, Ying, Griesel, Rulan, Jackson, Amanda, Sayed, Kaneez, Omar, Zaayid, Hill, Andrew, Ngwenya, Olina, van Zyl, Gert, Flowers, Tracy, Goemaere, Eric, Maartens, Gary, Meintjes, Graeme
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614301/
https://www.ncbi.nlm.nih.gov/pubmed/36706364
http://dx.doi.org/10.1097/QAI.0000000000003157

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7614301/
https://www.ncbi.nlm.nih.gov/pubmed/36706364
http://dx.doi.org/10.1097/QAI.0000000000003157

Ejemplares similares